Home LiteratureArticle Details
PMID: 8617220 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants.

The EMBO journal ·Vol. 15 ·No. 8 ·1996-04-15 ·Pages 1753-65

Buck M, Chojkier M

Abstract

Muscle wasting is a critical feature of patients afflicted by AIDS or cancer. In a murine model of muscle wasting, tumor necrosis factor alpha (TNF alpha) induces oxidative stress and nitric oxide synthase (NOS) in skeletal muscle, leading to decreased myosin creatinine phosphokinase (MCK) expression and binding activities. The impaired MCK-E box binding activities resulted from abnormal myogenin-Jun-D complexes, and were normalized by the addition of Jun-D, dithiothreitol or Ref-1, a nuclear redox protein. Treatment of skeletal muscle cells with a phorbol ester, a superoxide-generating system, an NO donor or a Jun-D antisense oligonucleotide decreased Jun-D activity and transcription from the MCK-E box, which were prevented by antioxidants, a scavenger of reducing equivalents, a NOS inhibitor and/or overexpression of Jun-D. The decreased body weight, muscle wasting and skeletal muscle molecular abnormalities of cachexia were prevented by treatment of TNF alpha mice with the antioxidants D-alpha-tocopherol of BW755c, or the NOS inhibitor nitro-L-arginine.

MeSH Terms
Animals Antioxidants/pharmacology Base Sequence CHO Cells Cachexia/etiology,pathology,prevention & control Cell Differentiation Creatine Kinase/genetics,metabolism Cricetinae DNA/genetics Disease Models, Animal Enhancer Elements, Genetic Humans Male Mice Mice, Nude Molecular Sequence Data Muscle, Skeletal/pathology Myosins/genetics,metabolism Nitric Oxide/biosynthesis Oxidative Stress Protein Binding Proto-Oncogene Proteins c-jun/metabolism Transfection Tumor Necrosis Factor-alpha/biosynthesis,genetics Weight Loss/drug effects
Chemicals
Antioxidants Proto-Oncogene Proteins c-jun Tumor Necrosis Factor-alpha Nitric Oxide DNA Creatine Kinase Myosins
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Buck M
Department of Medicine, Veterans Affairs Medical Center, San Diego, CA, USA.
Chojkier M
References (69)
69 references, click to expand
  1. Redox activation of Fos-Jun DNA binding activity is mediated by a DNA repair enzyme.
    EMBO J. 1992 Sep;11(9):3323-35 PMID: 1380454
  2. FGF inactivates myogenic helix-loop-helix proteins through phosphorylation of a conserved protein kinase C site in their DNA-binding domains.
    Cell. 1992 Dec 24;71(7):1181-94 PMID: 1335366
  3. Deficiency in rhabdomyosarcomas of a factor required for MyoD activity and myogenesis.
    Science. 1993 Mar 5;259(5100):1450-3 PMID: 8383879
  4. Glucocorticoids activate the ATP-ubiquitin-dependent proteolytic system in skeletal muscle during fasting.
    Am J Physiol. 1993 Apr;264(4 Pt 1):E668-76 PMID: 7682781
  5. Through thick and thin: wasting, obesity, and TNF alpha.
    Cell. 1993 May 21;73(4):625-7 PMID: 8500160
  6. Detection of endogenous malondialdehyde-deoxyguanosine adducts in human liver.
    Science. 1994 Sep 9;265(5178):1580-2 PMID: 8079172
  7. Getting a grip on myosin.
    Cell. 1994 Sep 9;78(5):733-7 PMID: 8087841
  8. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B.
    Cell. 1994 Sep 9;78(5):773-85 PMID: 8087845
  9. Redox signaling: nitrosylation and related target interactions of nitric oxide.
    Cell. 1994 Sep 23;78(6):931-6 PMID: 7923362
  10. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B.
    EMBO J. 1994 Nov 15;13(22):5433-41 PMID: 7957109
  11. Muscle deficiency and neonatal death in mice with a targeted mutation in the myogenin gene.
    Nature. 1993 Aug 5;364(6437):501-6 PMID: 8393145
  12. Myogenin gene disruption results in perinatal lethality because of severe muscle defect.
    Nature. 1993 Aug 5;364(6437):532-5 PMID: 8393146
  13. Transactivation by NF-IL6/LAP is enhanced by phosphorylation of its activation domain.
    Nature. 1993 Aug 5;364(6437):544-7 PMID: 8336793
  14. Depletion of the mitochondrial electron transport abrogates the cytotoxic and gene-inductive effects of TNF.
    EMBO J. 1993 Aug;12(8):3095-104 PMID: 8344250
  15. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds.
    Nature. 1993 Aug 12;364(6438):626-32 PMID: 8394509
  16. Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF-kappa B.
    Nature. 1993 Sep 9;365(6442):182-5 PMID: 8371761
  17. Tumor necrosis factor-alpha mediates changes in tissue protein turnover in a rat cancer cachexia model.
    J Clin Invest. 1993 Dec;92(6):2783-9 PMID: 8254032
  18. Tumor necrosis factor, other cytokines and disease.
    Annu Rev Cell Biol. 1993;9:317-43 PMID: 8280464
  19. LAP (NF-IL-6), a tissue-specific transcriptional activator, is an inhibitor of hepatoma cell proliferation.
    EMBO J. 1994 Feb 15;13(4):851-60 PMID: 7906646
  20. Mouse JunD negatively regulates fibroblast growth and antagonizes transformation by ras.
    Cell. 1994 Feb 25;76(4):747-60 PMID: 8124713
  21. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation.
    J Clin Invest. 1994 Jun;93(6):2379-86 PMID: 8200971
  22. Protein kinase A and C site-specific phosphorylations of LAP (NF-IL6) modulate its binding affinity to DNA recognition elements.
    J Clin Invest. 1994 Jun;93(6):2554-61 PMID: 8200992
  23. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1.
    J Exp Med. 1986 Jun 1;163(6):1433-50 PMID: 3486936
  24. Raised serum levels of tumour necrosis factor in parasitic infections.
    Lancet. 1986 Dec 13;2(8520):1364-5 PMID: 2878227
  25. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease.
    Lancet. 1987 Feb 14;1(8529):355-7 PMID: 2880163
  26. Tumors secreting human TNF/cachectin induce cachexia in mice.
    Cell. 1987 Aug 14;50(4):555-63 PMID: 3607879
  27. Acetaldehyde increases collagen gene transcription in cultured human fibroblasts.
    J Biol Chem. 1987 Dec 25;262(36):17690-5 PMID: 3693368
  28. Interleukin 1 and tumor necrosis factor do not regulate protein balance in skeletal muscle.
    Am J Physiol. 1987 Dec;253(6 Pt 1):C766-73 PMID: 3501247
  29. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.
    J Exp Med. 1988 Mar 1;167(3):1211-27 PMID: 3351436
  30. Tumor necrosis factor and the acute metabolic response to tissue injury in man.
    J Clin Invest. 1988 Oct;82(4):1321-5 PMID: 3139712
  31. DNA binding activities of three murine Jun proteins: stimulation by Fos.
    Cell. 1988 Dec 2;55(5):907-15 PMID: 3142691
  32. Prolonged activation of jun and collagenase genes by tumour necrosis factor-alpha.
    Nature. 1989 Feb 16;337(6208):661-3 PMID: 2537468
  33. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins.
    Am J Physiol. 1989 Mar;256(3 Pt 2):R659-65 PMID: 2784290
  34. A new DNA binding and dimerization motif in immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins.
    Cell. 1989 Mar 10;56(5):777-83 PMID: 2493990
  35. Infusion of tumor necrosis factor/cachectin promotes muscle catabolism in the rat. A synergistic effect with interleukin 1.
    J Clin Invest. 1989 May;83(5):1614-22 PMID: 2785120
  36. Anticachectin/tumor necrosis factor-alpha antibodies attenuate development of cachexia in tumor models.
    FASEB J. 1989 Jun;3(8):1956-62 PMID: 2721856
  37. Tumor necrosis factor and disease severity in children with falciparum malaria.
    N Engl J Med. 1989 Jun 15;320(24):1586-91 PMID: 2657427
  38. MyoD is a sequence-specific DNA binding protein requiring a region of myc homology to bind to the muscle creatine kinase enhancer.
    Cell. 1989 Sep 8;58(5):823-31 PMID: 2550138
  39. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor.
    Cell. 1989 Sep 8;58(5):923-31 PMID: 2476237
  40. Stimulation of collagen gene expression by ascorbic acid in cultured human fibroblasts. A role for lipid peroxidation?
    J Biol Chem. 1989 Oct 5;264(28):16957-62 PMID: 2777815
  41. Expression of two myogenic regulatory factors myogenin and MyoD1 during mouse embryogenesis.
    Nature. 1989 Sep 28;341(6240):303-7 PMID: 2552320
  42. Human fibroblasts release reactive oxygen species in response to interleukin-1 or tumour necrosis factor-alpha.
    Biochem J. 1989 Oct 15;263(2):539-45 PMID: 2556998
  43. Different members of the jun proto-oncogene family exhibit distinct patterns of expression in response to type beta transforming growth factor.
    J Biol Chem. 1990 Jan 25;265(3):1556-62 PMID: 2104845
  44. Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia.
    J Clin Invest. 1990 Jan;85(1):248-55 PMID: 2295699
  45. Differential gene expression of IFN-alpha and tumor necrosis factor-alpha in peripheral blood mononuclear cells from patients with AIDS related complex and AIDS.
    J Immunol. 1990 Feb 1;144(3):970-5 PMID: 2295823
  46. NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide.
    Proc Natl Acad Sci U S A. 1990 May;87(9):3629-32 PMID: 2333306
  47. Myogenin resides in the nucleus and acquires high affinity for a conserved enhancer element on heterodimerization.
    Genes Dev. 1990 Apr;4(4):582-95 PMID: 2163343
  48. MyoD binds cooperatively to two sites in a target enhancer sequence: occupancy of two sites is required for activation.
    Proc Natl Acad Sci U S A. 1990 Aug;87(15):5623-7 PMID: 2377600
  49. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF).
    FASEB J. 1990 Aug;4(11):2860-7 PMID: 2199284
  50. Redox regulation of fos and jun DNA-binding activity in vitro.
    Science. 1990 Sep 7;249(4973):1157-61 PMID: 2118682
  51. Elevation of tumor necrosis factor in head injury.
    J Neuroimmunol. 1990 Dec;30(2-3):213-7 PMID: 2229409
  52. LAP, a novel member of the C/EBP gene family, encodes a liver-enriched transcriptional activator protein.
    Genes Dev. 1990 Sep;4(9):1541-51 PMID: 2253878
  53. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload.
    J Clin Invest. 1990 Dec;86(6):1991-8 PMID: 2123889
  54. Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia.
    J Clin Invest. 1990 Dec;86(6):2014-24 PMID: 2254457
  55. Evidence that tumor necrosis factor plays a pathogenetic role in the paraneoplastic syndromes of cachexia, hypercalcemia, and leukocytosis in a human tumor in nude mice.
    J Clin Invest. 1991 Mar;87(3):977-85 PMID: 1999505
  56. c-JUN, JUN B, and JUN D differ in their binding affinities to AP-1 and CRE consensus sequences: effect of FOS proteins.
    Oncogene. 1991 Apr;6(4):533-42 PMID: 1827665
  57. d-alpha-tocopherol inhibits collagen alpha 1(I) gene expression in cultured human fibroblasts. Modulation of constitutive collagen gene expression by lipid peroxidation.
    J Clin Invest. 1991 Jun;87(6):2230-5 PMID: 2040703
  58. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1.
    EMBO J. 1991 Aug;10(8):2247-58 PMID: 2065663
  59. The reductive half-reaction of xanthine oxidase. Identification of spectral intermediates in the hydroxylation of 2-hydroxy-6-methylpurine.
    J Biol Chem. 1991 Dec 15;266(35):23724-31 PMID: 1660883
  60. Functional antagonism between c-Jun and MyoD proteins: a direct physical association.
    Cell. 1992 Feb 7;68(3):507-19 PMID: 1310896
  61. Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity.
    EMBO J. 1992 Feb;11(2):653-65 PMID: 1537340
  62. Fos and Jun repress transcriptional activation by myogenin and MyoD: the amino terminus of Jun can mediate repression.
    Genes Dev. 1992 Apr;6(4):676-89 PMID: 1313772
  63. Activation of the myogenic lineage by MEF2A, a factor that induces and cooperates with MyoD.
    Science. 1994 Nov 18;266(5188):1236-40 PMID: 7973707
  64. Nitric oxide in skeletal muscle.
    Nature. 1994 Dec 8;372(6506):546-8 PMID: 7527495
  65. Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase.
    Science. 1995 Feb 17;267(5200):1022-4 PMID: 7863328
  66. Malondialdehyde-modified low density lipoproteins in patients with atherosclerotic disease.
    J Clin Invest. 1995 Jun;95(6):2611-9 PMID: 7769103
  67. Cachectin and tumour necrosis factor as two sides of the same biological coin.
    Nature. 1986 Apr 17-23;320(6063):584-8 PMID: 3010124
  68. Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
    J Clin Invest. 1992 May;89(5):1681-4 PMID: 1569207
  69. Cachexia and graft-vs.-host-disease-type skin changes in keratin promoter-driven TNF alpha transgenic mice.
    Genes Dev. 1992 Aug;6(8):1444-56 PMID: 1379563
Article Info
Journal
The EMBO journal
Abbr.
EMBO J
ISSN
0261-4189
Published
1996-04-15
Pages
1753-65
Language
English
Region
England
NLM ID
8208664
PMCID
PMC450091
Subset
IM
Grants
NIDDK NIH HHS · DK-38652 · United States
NIDDK NIH HHS · DK-46971 · United States
NIGMS NIH HHS · GM-41804 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com